CBX3-targeted dual BET/PLK1 inhibition amplifies the effects of CDK4/6 inhibitors by disrupting BRD4/PLK1-mediated transcription and inducing cell-cycle arrest in prostate cancer (178). This evidence concerns the gene PLK1 and prostate cancer.